secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2026-05-14T20:06:06+00:00
Accession:  0001104659-26-061150
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027
---------------------------------------------------------------------------

- Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
- Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.
- Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.
- Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.
- Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/0001104659-26-061150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/elut-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer